PLX Protalix BioTherapeutics, Inc.

8-K Current Report

Filed: March 18, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Protalix BioTherapeutics, Inc. (PLX) 8-K current report filed with SEC EDGAR on March 18, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• FY 2025 financial results and business update announced via press release on March 18, 2026
• Financial details and clinical progress to be found in Exhibit 99.1 of this 8-K filing

+2 more insights

Other Protalix BioTherapeutics, Inc. 8-K Filings

8-K Mar 9, 2026

Get deeper insights on Protalix BioTherapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.